C-peptide appears in studies for two very different reasons: researchers may measure it to learn about insulin secretion, or administer a defined preparation to test a proposed effect. Confusing these roles can make a well-established measurement look like proof of a treatment. This reference explains the distinction and the evidence needed for each.
Identify the connecting segment and its separate product
The original isotope-dilution assay paper on C-peptide describes a 31-residue human peptide released through proinsulin cleavage. Insulin and C-peptide are produced in equimolar amounts through that processing relationship.Human C-peptide isotope-dilution assay study (opens in a new tab)
Equimolar means equal numbers of molecules, not equal masses. It also does not mean that a blood sample must contain equal concentrations after the molecules have circulated and undergone different clearance processes.
In a proinsulin structure, the connecting region is still part of a larger molecule. In a C-peptide measurement, the intended analyte is the processed peptide. An assay needs to distinguish that analyte from related material sufficiently for its purpose.
| Role | Question |
|---|---|
| Part of proinsulin | How is the precursor organised and processed? |
| Measured analyte | What does the concentration reveal about secretion? |
| Administered intervention | Does the tested preparation change an outcome? |
A concentration is not an instantaneous secretion rate
Polonsky and colleagues studied biosynthetic human C-peptide kinetics in ten healthy volunteers and seven people with type 1 diabetes. During changing infusion rates, peripheral concentrations did not change in direct proportion to the rate entering the system.Polonsky and colleagues — Biosynthetic C-peptide and secretion estimates (opens in a new tab)
A two-compartment model using participant-specific kinetic information allowed the investigators to estimate the input more accurately. The study tested the model against known administered quantities.Polonsky and colleagues — Biosynthetic C-peptide and secretion estimates (opens in a new tab)
The practical reading lesson is that a concentration curve contains information about distribution and removal as well as secretion. A lingering concentration after the input falls is not necessarily evidence that secretion remains equally high.
What a long-acting C-peptide trial actually found
Wahren and colleagues’ 2016 trial studied a pegylated, long-acting C-peptide preparation in 250 people with type 1 diabetes and peripheral neuropathy over 52 weeks. It assessed nerve conduction, vibration perception and a clinical neuropathy score.Wahren and colleagues — Long-acting C-peptide and neuropathy (opens in a new tab)
Sural nerve conduction improved from baseline in the treated groups, but it also improved in the placebo group. The study did not establish a treatment benefit on that measure or the clinical score; vibration perception improved relative to placebo.Wahren and colleagues — Long-acting C-peptide and neuropathy (opens in a new tab)
The within-group improvement therefore cannot be quoted as proof that treatment improved nerve conduction. The relevant efficacy comparison is the difference from placebo.
The tested preparation was pegylated, so its results should also remain attached to that intervention. They cannot simply be reassigned to every material bearing the native C-peptide name.
Use the right evidence for the claim being made
A paper validating C-peptide quantification can support an analytical measurement. A kinetic study can support a secretion estimate under its model assumptions. A controlled intervention trial is needed to evaluate a proposed clinical effect.
These evidence streams can inform one another, but none automatically completes the others. Accurate measurement does not prove treatment benefit, and a physiological rationale does not resolve an unsuccessful clinical endpoint.
When recording a new study, specify whether C-peptide is a predictor, outcome or administered material. Then preserve its molecular form and the measured endpoint so the finding enters the correct evidence record.
This separation keeps the reference useful for understanding research. Individual test interpretation and treatment decisions require clinical context and are outside this article’s scope.
Sources and further detail
- Human C-peptide isotope-dilution assay study (opens in a new tab)
Original analytical paper’s identity and processing context read. Used for 31-residue identity and equimolar origin; assay preparation instructions not reproduced.
- Polonsky and colleagues — Biosynthetic C-peptide and secretion estimates (opens in a new tab)
Original 1986 indexed abstract/results and publisher-hosted paper passages read. Known input, non-steady concentration behaviour and model-based estimation distinguished.
- Wahren and colleagues — Long-acting C-peptide and neuropathy (opens in a new tab)
Original 2016 publisher abstract and outcome results read. Pegylated intervention, placebo nerve-conduction improvement and mixed endpoints retained without administration guidance.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.